XPO1 and plasma cell myeloma: One of the most promising, Selinexor, targets exportin 1 (Xpo1) and is currently in pre-clinical trials and has shown efficacy against acute myeloid leukemia and multiple myeloma (Kashyap et al., 2016; Mahipal and Malafa, 2016).